Kristy Hawkins
Kristy has over 20 years of experience in the field of synthetic biology focusing on yeast metabolic engineering for the production of small molecules. She did the founding work on the benzylisoquinoline alkaloid pathway while earning a Ph.D. in chemical engineering at Caltech and gained valuable industry experience at both Amyris and Lygos. Kristy is an expert in tool development, HTP screening, and host strain and heterologous pathway engineering. In 2015, she began her current role as a co-founder of Antheia with Prof. Christina Smolke and serves as the Chief Scientific Officer. Antheia is transforming pharmaceutical supply chains by developing biomanufacturing processes for essential medicines inspired by nature and has successfully launched their first product.
Antheia
Maxing Bioprocesses At Scale By Targeting Heterogeneity – An Industry Perspective
-
Controlling cell-to-cell variations in fermentation tanks from lab-scale to large-commercial scale poses challenges but can create immense value, unleashing the full potential of the process. Recent advances in understanding and measuring fermentation heterogeneity have created a new focus on cell heterogeneity, and SynBio technologies to intelligently promote the best cell variants. Join us when leading industry experts discuss how mitigating cell-to-cell variation helps them unlock value in their fermentations and hear them share recent experience.
Conference Pass
2,495
USD
Keynotes & Firesides
Workshops & Breakouts
1:1 Partnering App
Meals & Receptions
Session Recordings
Until Friday April 25th
Full Rate:
$3,495
